Open AccessValidation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population
Author(s) -
Éric Vigneault,
Josée Savard,
MarieHélène Savard,
Hans Ivers,
Philippe Després,
William Foster,
André-Guy Martin,
Vincent Fradet
Publication year - 2017
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.477
H-Index - 38
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.4428
Subject(s) - prostate cancer , medicine , cronbach's alpha , prostatectomy , quality of life (healthcare) , construct validity , epic , cancer , gynecology , clinical psychology , psychometrics , art , nursing , literature
This study aims to empirically validate the French- Canadian version of the Expanded Prostate Cancer Index Composite (EPIC), a measure of health-related quality of life for prostate cancer patients.Methods: Two hundred fifty-one participants completed a battery of self-report scales, including the French-Canadian version of the EPIC, after having received radiation therapy or radical prostatectomy for prostate cancer.Results: The internal consistency for the urinary incontinence, bowel, and sexual domains of the EPIC-26 was high (Cronbach’s alpha coefficients from 0.80‒0.92), while coefficients for the urinary irritation/obstruction (0.59) and hormonal (0.67) domains were lower. Item-total correlations (rs=0.15‒0.85), and temporal stability (rs=0.72‒0.93) generally supported the reliability of the instrument. The five-factor structure of the EPIC-26 was confirmed for the most part. The construct validity of the instrument was also supported by high correlations obtained between each domain and measures assessing similar constructs (rs=-0.56‒0.83). The EPIC also showed an excellent sensitivity to change with significant differences obtained on EPIC scores (all p<0.05) between pre- and post-prostate cancer treatment.Conclusions: The psychometric qualities of the French-Canadian version of the EPIC are well-supported, thus providing a valid tool to assess health-related quality of life in prostate cancer patients.